What is the confirmed 2025 market size and projected 2035 value for the veterinary pain management market?
The market was valued at USD 2,784.8 million in 2025 and is projected to reach USD 5,162.9 million by 2035 at a 7.1% CAGR. Anti-NGF mAb biologics (Librela, Solensia) are the fastest-growing product category. NSAIDs are the dominant pharmaceutical category by prescription volume. Companion animals are the dominant species. OA is the largest indication. North America leads; Asia-Pacific grows fastest from biologic market access expansion.

Why did anti-NGF mAb biologics (Librela, Solensia) create a new companion animal pain management category above conventional NSAIDs?
Conventional oral NSAIDs (meloxicam, carprofen) for canine OA pain management require chronic daily owner-administered oral dosing — with GI adverse effects (vomiting, diarrhoea, GI ulceration) and risk of hepato-renal toxicity limiting use in older dogs with concurrent metabolic disease, and with owner oral dosing compliance declining over time in dogs resisting oral medication. Monthly SC clinic-administered Librela injection eliminates owner compliance barriers, avoids GI/hepato-renal adverse effect risk, and produces pain reduction through a distinct NGF pathway mechanism complementary to NSAID COX inhibition. For feline OA, Solensia created the first effective monthly dosing option — chronic oral NSAID feline compliance has historically been poor from palatability and handling difficulties in cats.

How does multimodal pain protocol adoption sustain simultaneous pharmaceutical and non-pharmaceutical pain management market growth?
WSAVA (World Small Animal Veterinary Association) and IVAPM (International Veterinary Academy of Pain Management) OA pain management guidelines recommending multimodal protocols — combining pharmacological management (NSAID and/or anti-NGF mAb), physical rehabilitation (hydrotherapy, physiotherapy, therapeutic laser/PBM), joint supplements (glucosamine/chondroitin, omega-3), and weight management — create simultaneous demand across pharmaceutical and equipment/supplement market segments from each companion animal OA patient. Each OA patient managed on a complete multimodal protocol consumes NSAID or biologic prescriptions, laser therapy sessions, joint supplement products, and rehabilitation professional services — growing multiple market segments simultaneously from a single patient.

What is driving veterinary cancer pain management as the fastest-growing pain indication by growth rate?
Companion animal cancer pain management — opioids (buprenorphine, fentanyl CRI, tramadol), NSAIDs (for tumour-associated inflammation), gabapentinoids (neuropathic cancer pain), and ketamine CRI (refractory cancer pain) — is the fastest-growing pain indication by growth rate from expanding companion animal cancer diagnosis through screening programmes. Each cancer-diagnosed companion animal patient generates pain management pharmaceutical demand throughout diagnosis workup, cancer treatment (chemotherapy, surgery), and palliative or end-of-life care — creating a growing cancer pain pharmaceutical demand stream above the established OA and post-operative pain market.

How do gabapentinoids and NMDA receptor antagonists expand companion animal pain management beyond NSAIDs and opioids?
Gabapentin and pregabalin — targeting voltage-gated calcium channels to reduce neuropathic pain signalling — and ketamine (NMDA receptor antagonist providing CRI analgesia and opioid-sparing effects) represent adjunct analgesic mechanisms beyond NSAID COX inhibition and opioid mu-receptor agonism. Multimodal analgesia protocols routinely incorporate gabapentin for neuropathic OA pain, post-TPLO chronic pain management, and cancer-associated neuropathic pain. Ketamine CRI protocols for companion animal ICU pain management and post-operative analgesia sustain opioid-sparing combined with NMDA receptor antagonism — growing gabapentinoid and NMDA antagonist prescription volumes as multimodal protocol adoption increases.

Which regional markets are growing fastest for veterinary pain management?
Asia-Pacific is the fastest-growing regional veterinary pain management market from companion animal OA biologic market access expansion — with Librela and Solensia gaining regulatory approval and market penetration in Japan, South Korea, Australia, and China — creating the first significant companion animal OA pain biologic prescription market in Asian companion animal practice. Europe is a significant and growing market from NSAID prescription growth and Librela/Solensia European market adoption growing the anti-NGF mAb companion animal OA prescription base above North American baseline.